Daewoong Pharmaceutical announced on the 19th of June the signing of an Agreement for license and distribution of potassium-competitive acid blocker (P-CAB) type drug Fexuprazan to Morocco. The partnering company is Cooper Pharma. The Agreement is worth about USD 20.32 million (equivalent to KRW 27 billion) and the local release of Fexuprazan in Morocco is scheduled for 2025.

Cooper Pharma will carry out active marketing campaigns for the sale of Fexuprazan for a term of 10 years in the Moroccan market.